Q-omics provides the consensus-scored LILRB4 profile across patient tissues and cancer cell-line models. LILRB4 expression is associated with patient survival in 30 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, LILRB4 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, LILRB4 RNA expression shows 18,687 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight SKCM, KIRC, and GBM as cancer lineages where LILRB4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LILRB4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LILRB4 survival associations across molecular data types. LILRB4 RNA expression shows survival associations in the most cancer types (30), followed by mutation status (7) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LILRB4 RNA expression–survival associations across cancer types. High LILRB4 expression shows unfavorable associations in LGG, LAML and KIRC, but favorable associations in SKCM, HNSC and CESC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for LILRB4 RNA expression.
This table summarizes LILRB4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for LILRB4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LILRB4 shows higher tumor expression in KIRC, HNSC, KIRP, STAD, THCA and BRCA. The KIRC box plot shows higher LILRB4 RNA expression in tumor versus normal tissue (log2 FC = +2.606, t-test p < 0.001).
This table shows molecular features associated with LILRB4 in patient tissues and cancer cell lines. In patient samples, LILRB4 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, LILRB4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
